Stockscreener 앱 받기
147.38
1.01%
-1.56
시간 외 거래:
151.00
3.62
+2.46%
전일 마감가:
$148.94
열려 있는:
$147.38
하루 거래량:
1.31M
Relative Volume:
1.49
시가총액:
$14.62B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
49.96
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+3.35%
1개월 성능:
+3.82%
6개월 성능:
+38.48%
1년 성능:
+26.88%
1일 변동 폭
$146.62
$149.98
1주일 범위
$141.26
$149.98
52주 변동 폭
$84.23
$154.61
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
147.38 | 14.77B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
145.43 | 65.38B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 44.75B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.10 | 40.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.79 | 22.50B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
415.34 | 19.04B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyLayoff News & Community Verified Watchlist Alerts - newser.com
Can Neurocrine Biosciences Inc. stock sustain revenue growthQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsMarket Trend Review & Free Real-Time Volume Trigger Notifications - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikesEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com
Can Neurocrine Biosciences Inc. stock hit analyst price targetsWeekly Gains Report & Daily Risk Controlled Trade Plans - Fundação Cultural do Pará
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Short interest data insights for Neurocrine Biosciences Inc.Portfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levelsMarket Rally & Risk Controlled Stock Pick Alerts - Fundação Cultural do Pará
What moving averages say about Neurocrine Biosciences Inc.Insider Selling & Low Risk High Win Rate Stock Picks - newser.com
Neurocrine Biosciences (NBIX): Fresh INGREZZA Study Data Renews Focus on Valuation - simplywall.st
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo
Is Neurocrine Biosciences Inc a good long term investmentShort-Term Trading Alerts & You’ll Thank Yourself in 6 Months - earlytimes.in
Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025 - Yahoo Finance
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
1.34%
자본화:
|
볼륨(24시간):